A 28-year-old G2P1 woman at 35 weeks gestation is admitted with the second episode of painless vaginal bleeding (first episode 1 week ago, 150 mL; current episode 300 mL over 4 hours). She is hemodynamically stable (BP 126/78, HR 88). Transabdominal ultrasound confirms total placenta previa. Fetal monitoring shows baseline FHR 140 bpm with good variability and no decelerations. She has received one course of corticosteroids 1 week ago. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **total placenta previa with recurrent bleeding** (second episode within 1 week, escalating volume: 150 mL → 300 mL) at **35 weeks gestation**. Despite hemodynamic stability and reassuring fetal status, the pattern of recurrent hemorrhage changes management. ## Decision Framework: When to Deliver in Placenta Previa ### Indicators for Elective Delivery **Key Point:** Delivery is indicated when: 1. **Gestational age ≥34 weeks** (acceptable neonatal outcome) 2. **Recurrent bleeding** despite hospitalization and pelvic rest 3. **Completed one course of corticosteroids** (fetal lung maturity optimized) 4. **Hemodynamically stable** (no massive hemorrhage) 5. **Reassuring fetal status** (no compromise) ### Why 35 Weeks Justifies Delivery | Gestational Age | Neonatal Outcome | Delivery Indication | | --- | --- | --- | | <34 weeks | High morbidity/mortality | Expectant unless life-threatening hemorrhage | | 34–36 weeks | Acceptable with NICU support | Deliver if recurrent bleeding or complications | | ≥37 weeks | Minimal prematurity risk | Elective cesarean (standard) | **High-Yield:** At 35 weeks with recurrent bleeding and completed corticosteroid course, the risk-benefit ratio favors delivery. Neonatal morbidity is acceptable, and continued expectant management risks further hemorrhage and potential maternal hemorrhagic shock. ### Specific Indications in This Case 1. **Recurrent bleeding pattern:** First bleed 1 week ago (150 mL), now 300 mL—escalating severity suggests placental instability 2. **Corticosteroid course complete:** One full course given 1 week ago; repeat course not indicated (no additional benefit beyond 7 days) 3. **Gestational age 35 weeks:** Neonatal survival >99%, respiratory distress manageable with NICU support 4. **Stable maternal hemodynamics:** No contraindication to planned cesarean delivery 5. **Reassuring fetal status:** No signs of fetal anemia or compromise **Clinical Pearl:** Recurrent bleeding in placenta previa is a **relative indication for delivery** once gestational age permits (≥34 weeks). Each bleed risks further hemorrhage, and the cumulative blood loss may exceed maternal tolerance. ## Cesarean Delivery Technique - **Anesthesia:** Spinal anesthesia is safe in a hemodynamically stable patient; general anesthesia reserved for massive hemorrhage or hemodynamic instability - **Preparation:** Blood products (2 units PRBC, FFP, platelets) should be cross-matched and available - **Surgical approach:** Lower segment cesarean section; avoid placental site if possible - **Hemorrhage control:** Oxytocin infusion, uterine compression, or rarely, uterine artery ligation if massive bleeding ## Why Not the Other Options? - **Continue expectant management (Option A):** Recurrent bleeding pattern indicates placental instability. Waiting until 37 weeks risks further hemorrhage and potential maternal hemorrhagic shock. At 35 weeks, neonatal benefit of 2 more weeks does not outweigh maternal risk. - **Repeat corticosteroids (Option A component):** No benefit if given >7 days after first course; not indicated - **Amniocentesis (Option C):** Unnecessary and contraindicated in placenta previa (risk of placental puncture and hemorrhage). Fetal lung maturity is assumed acceptable at 35 weeks with prior corticosteroid course - **Tocolytics (Option D):** No indication; patient is not in labor. Tocolytics do not prevent recurrent bleeding and may delay necessary delivery